GB0514501D0 - Pharmaceutical compounds - Google Patents

Pharmaceutical compounds

Info

Publication number
GB0514501D0
GB0514501D0 GBGB0514501.6A GB0514501A GB0514501D0 GB 0514501 D0 GB0514501 D0 GB 0514501D0 GB 0514501 A GB0514501 A GB 0514501A GB 0514501 D0 GB0514501 D0 GB 0514501D0
Authority
GB
United Kingdom
Prior art keywords
pharmaceutical compounds
involuntary
dihydrotetrabenazine
twitches
tremors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0514501.6A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cambridge Laboratories Ireland Ltd
Original Assignee
Cambridge Laboratories Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Laboratories Ireland Ltd filed Critical Cambridge Laboratories Ireland Ltd
Priority to GBGB0514501.6A priority Critical patent/GB0514501D0/en
Publication of GB0514501D0 publication Critical patent/GB0514501D0/en
Priority to MEP-2008-916A priority patent/ME01629B/me
Priority to CNA2006800339758A priority patent/CN101282726A/zh
Priority to DE602006002982T priority patent/DE602006002982D1/de
Priority to JP2008520952A priority patent/JP2009501202A/ja
Priority to ES06764942T priority patent/ES2314931T3/es
Priority to HR20080677T priority patent/HRP20080677T3/xx
Priority to DK06764942T priority patent/DK1885363T3/da
Priority to AT06764942T priority patent/ATE409481T1/de
Priority to KR1020087003481A priority patent/KR20080030666A/ko
Priority to SI200630147T priority patent/SI1885363T1/sl
Priority to PCT/GB2006/002593 priority patent/WO2007007105A1/en
Priority to RSP-2008/0492A priority patent/RS50626B/sr
Priority to EP06764942A priority patent/EP1885363B1/en
Priority to EP08017191A priority patent/EP2027861B1/en
Priority to RU2008105590/15A priority patent/RU2409365C2/ru
Priority to AU2006268098A priority patent/AU2006268098B2/en
Priority to NZ565522A priority patent/NZ565522A/en
Priority to CA002615077A priority patent/CA2615077A1/en
Priority to PT06764942T priority patent/PT1885363E/pt
Priority to AT08017191T priority patent/ATE522215T1/de
Priority to US11/995,436 priority patent/US20080319000A1/en
Priority to HK08105582.5A priority patent/HK1111085B/en
Priority to PL06764942T priority patent/PL1885363T3/pl
Priority to ZA200800905A priority patent/ZA200800905B/xx
Priority to CY20081101475T priority patent/CY1108653T1/el
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
GBGB0514501.6A 2005-07-14 2005-07-14 Pharmaceutical compounds Ceased GB0514501D0 (en)

Priority Applications (26)

Application Number Priority Date Filing Date Title
GBGB0514501.6A GB0514501D0 (en) 2005-07-14 2005-07-14 Pharmaceutical compounds
MEP-2008-916A ME01629B (me) 2005-07-14 2006-05-31 Upotreba 3,11 b-cis-dihidrotetrabenazina za tretman simptoma huntington-ove bolesti
ZA200800905A ZA200800905B (en) 2005-07-14 2006-07-13 Use of 3,11B-CIS-Dihydrotetrabenazine for the treatment of symptoms of huntington's disease
RSP-2008/0492A RS50626B (sr) 2005-07-14 2006-07-13 Upotreba 3,11b-cis-dihidrotetrabenazina za tretman simptoma huntington-ove bolesti
RU2008105590/15A RU2409365C2 (ru) 2005-07-14 2006-07-13 ПРИМЕНЕНИЕ 3,11b-ЦИС-ДИГИДРОТЕТРАБЕНАЗИНА ДЛЯ ЛЕЧЕНИЯ СИМПТОМОВ БОЛЕЗНИ ГЕНТИНГТОНА
JP2008520952A JP2009501202A (ja) 2005-07-14 2006-07-13 ハンチントン病の症状の治療のための３，１１ｂ−シス−ジヒドロテトラベナジンの使用
ES06764942T ES2314931T3 (es) 2005-07-14 2006-07-13 Utilizacion de 3,11b-cis-dihidrotetrabenazina para el tratamiento de sintomas de la enfermedad de huntington.
HR20080677T HRP20080677T3 (hr) 2005-07-14 2006-07-13 Uporaba 3,11 b-cis-dihidrotetrabenazina u liječenju simptoma huntington-ove bolesti
DK06764942T DK1885363T3 (da) 2005-07-14 2006-07-13 Anvendelse af 3,11b-cis-dihydrotetrabenazin til behandling af symptomer på Huntingtons chorea
AT06764942T ATE409481T1 (de) 2005-07-14 2006-07-13 Verwendung von 3,11b-cis-dihydrotetrabenazin zur behandlung von symptomen der huntington-krankheit
KR1020087003481A KR20080030666A (ko) 2005-07-14 2006-07-13 헌팅턴병의 증상의 치료를 위한３,１１ｂ-시스-디하이드로테트라베나진의 용도
SI200630147T SI1885363T1 (sl) 2005-07-14 2006-07-13 Uporaba 3,11b-cis-dihidrotetrabenazina za zdravljenje simptomov Huntingtonove bolezni
PCT/GB2006/002593 WO2007007105A1 (en) 2005-07-14 2006-07-13 Use of 3,1ib-cis-dihydrotetrabenazine for the treatment of symptons of huntington' s disease
CNA2006800339758A CN101282726A (zh) 2005-07-14 2006-07-13 3，11b-顺-二氢丁苯喹嗪用于治疗亨廷顿病症状的用途
EP06764942A EP1885363B1 (en) 2005-07-14 2006-07-13 Use of 3,11b-cis-dihydrotetrabenazine for the treatment of symptoms of huntington' s disease
EP08017191A EP2027861B1 (en) 2005-07-14 2006-07-13 Use of 3,11b-cis-dihydrotetrabenazine for the treatment of symptoms of Huntington's disease
DE602006002982T DE602006002982D1 (de) 2005-07-14 2006-07-13 Verwendung von 3,11b-cis-dihydrotetrabenazin zur behandlung von symptomen der huntington-krankheit
AU2006268098A AU2006268098B2 (en) 2005-07-14 2006-07-13 Use of 3,1IB-CIS-dihydrotetrabenazine for the treatment of symptoms of Huntington's disease
NZ565522A NZ565522A (en) 2005-07-14 2006-07-13 Use of 3,11b-cis-dihydrotetrabenazine for the treatment of symptoms of Huntington's disease
CA002615077A CA2615077A1 (en) 2005-07-14 2006-07-13 Use of 3,1ib-cis-dihydrotetrabenazine for the treatment of symptoms of huntington's disease
PT06764942T PT1885363E (pt) 2005-07-14 2006-07-13 Utilização de 3,1-1b-cis-di-hidrotetrabenazina para o tratamento dos sintomas da doença de huntington
AT08017191T ATE522215T1 (de) 2005-07-14 2006-07-13 Verwendung von 3,11b-cis-dihydrotetrabenazine zur behandlung von symptomen von huntington-chorea
US11/995,436 US20080319000A1 (en) 2005-07-14 2006-07-13 Use of 3,1IB-Cis-Dihydrotetrabenazine for the Treatment of Symptoms of Huntingtons Disease
HK08105582.5A HK1111085B (en) 2005-07-14 2006-07-13 Use of 3,11b-cis-dihydrotetrabenazine for the treatment of symptoms of huntington' s disease
PL06764942T PL1885363T3 (pl) 2005-07-14 2006-07-13 Zastosowanie 3,11b-cis-dihydrotetrabenzyny do leczenia objawów choroby Huntingtona
CY20081101475T CY1108653T1 (el) 2005-07-14 2008-12-22 Η εφευρεση αυτη σχετιζεται με τη χρηση διυδpotetpabenazinhς στην θεραπαυτικη αντιμετωπιση της νοσου huntington

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0514501.6A GB0514501D0 (en) 2005-07-14 2005-07-14 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
GB0514501D0 true GB0514501D0 (en) 2005-08-24

Family

ID=34897233

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0514501.6A Ceased GB0514501D0 (en) 2005-07-14 2005-07-14 Pharmaceutical compounds

Country Status (23)

Country Link
US (1) US20080319000A1 (enExample)
EP (2) EP2027861B1 (enExample)
JP (1) JP2009501202A (enExample)
KR (1) KR20080030666A (enExample)
CN (1) CN101282726A (enExample)
AT (2) ATE522215T1 (enExample)
AU (1) AU2006268098B2 (enExample)
CA (1) CA2615077A1 (enExample)
CY (1) CY1108653T1 (enExample)
DE (1) DE602006002982D1 (enExample)
DK (1) DK1885363T3 (enExample)
ES (1) ES2314931T3 (enExample)
GB (1) GB0514501D0 (enExample)
HR (1) HRP20080677T3 (enExample)
ME (1) ME01629B (enExample)
NZ (1) NZ565522A (enExample)
PL (1) PL1885363T3 (enExample)
PT (1) PT1885363E (enExample)
RS (1) RS50626B (enExample)
RU (1) RU2409365C2 (enExample)
SI (1) SI1885363T1 (enExample)
WO (1) WO2007007105A1 (enExample)
ZA (1) ZA200800905B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2410947B (en) * 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds
GB0516168D0 (en) * 2005-08-05 2005-09-14 Cambridge Lab Ireland Ltd Pharmaceutical compounds
AU2007317242B2 (en) 2006-11-08 2013-08-01 Neurocrine Biosciences, Inc. Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11B-hexahydro-2H-pyrido[2,1-a] isoquinolin-2-ol compounds and methods relating thereto
GB0810857D0 (en) * 2008-06-13 2008-07-23 Cambridge Lab Ireland Ltd Pharmaceutical compounds
GB2462611A (en) * 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
US20110053866A1 (en) * 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
US20120208773A1 (en) * 2008-08-12 2012-08-16 Valeant International (Barbados) Srl Pharmaceutical compositions with tetrabenazine
GB2463451A (en) * 2008-09-08 2010-03-17 Cambridge Lab 3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia
GB2463283A (en) * 2008-09-08 2010-03-10 Cambridge Lab 3,11b-cis-dihydrotetrabenazine for use in treating asthma
GB2463452A (en) * 2008-09-08 2010-03-17 Cambridge Lab Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof
JP2013501810A (ja) * 2009-08-12 2013-01-17 ヴァリーント インターナショナル（バルバドス）エスアールエル 医薬組成物
JP2013527237A (ja) * 2010-06-01 2013-06-27 オースペックス・ファーマシューティカルズ・インコーポレイテッド ベンゾキノロン系ｖｍａｔ２阻害剤
WO2012095548A2 (es) 2011-01-13 2012-07-19 Centro De Investigación Biomédica En Red De Enfermedades Neurodegenerativas (Ciberned) Compuestos para el tratamiento de enfermedades neurodegenerativas
GB201705302D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705306D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
JP7250692B2 (ja) * 2017-04-01 2023-04-03 アデプティオ ファーマシューティカルズ リミテッド 運動障害の治療における使用のためのジヒドロテトラベナジン
GB201705304D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705303D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
TWI832854B (zh) 2018-04-25 2024-02-21 美商神經治療股份有限公司 丁苯那嗪經皮輸送裝置
GB201808464D0 (en) * 2018-05-23 2018-07-11 Adeptio Pharmaceuticals Ltd Pharmaceutical compounds for use in treating huntington's disease
JP2022541021A (ja) * 2019-07-16 2022-09-21 ラッシュ・ユニバーシティ・メディカル・センター 神経変性障害を治療するためのベンゾエート含有組成物の使用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2830993A (en) * 1958-04-15 Quinolizine derivatives
US3159638A (en) * 1964-12-01 Xcha-chj
US3314966A (en) * 1967-04-18 Substituted benzo[a]quinolizines
US2954382A (en) * 1960-09-27 Xpreparation of hexahydrobenzoquinol-
US3132147A (en) * 1964-05-05
US3209005A (en) * 1965-09-28 Hexahydro-llbh-benzo[a] quinolizines and processes therefor
US3095419A (en) * 1963-06-25 Process for preparing z-oxo-j-
US3123609A (en) * 1964-03-03 Benzo
US3079395A (en) * 1963-02-26 Novel z-oxq-benzoquinoliaine
US3009918A (en) * 1961-11-21 Chz ch
US3053845A (en) * 1962-09-11 Benzofykedocolines
US2843591A (en) * 1958-07-15 Method for preparing same
US3045021A (en) * 1959-09-24 1962-07-17 Hoffmann La Roche Preparation of substituted 2-oxobenzoquinolizines
GB999092A (en) * 1959-11-24 1965-07-21 Wellcome Found Method for making benzo(a)-quinolizine derivatives
US3375254A (en) * 1961-09-29 1968-03-26 Burroughs Wellcome Co Manufacture of 1, 2, 3, 4, 6, 7-hexahydro-2-oxo-11bh-benzo(a)quinolizines
US3105079A (en) * 1961-12-29 1963-09-24 Pfizer & Co C 10-aminobenzopyridocolines
US3390152A (en) * 1965-10-21 1968-06-25 Abbott Lab 9, 10-alkoxy-3-alkyl-2, 2-(dithiosubstituted)-benzoquinolizines
JPS4836303B1 (enExample) * 1968-12-27 1973-11-02
US3635986A (en) * 1969-12-22 1972-01-18 Miles Lab 2-substituted amino-hexahydrobenzo(a)quinolizines
YU264675A (en) * 1974-10-23 1982-05-31 Chinoin Gyogyszer Es Vegyeszet Process for obtaining benzo (a)-quinolizidine derivatives
GB1513824A (en) * 1975-05-22 1978-06-14 Wyeth John & Brother Ltd 1,3,4,6,7,11b-hexahydro-2h-benzo(a)quinolizine derivative
US4133812A (en) * 1975-11-21 1979-01-09 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. Process for producing benzo (a) quinolizine derivatives
US4304913A (en) * 1978-11-20 1981-12-08 Miles Laboratories, Inc. Trans-2-substituted-amido-hexahydrobenzo [A]quinolizines
US4353656A (en) * 1980-10-14 1982-10-12 Xerox Corporation Moving coil, multiple energy print hammer system including a closed loop servo
US4778054A (en) * 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
FI88112C (fi) * 1985-07-30 1993-04-13 Glaxo Group Ltd Anordning foer administrering av laekemedel till patienter
GB9004781D0 (en) * 1990-03-02 1990-04-25 Glaxo Group Ltd Device
US6087376A (en) * 1997-02-05 2000-07-11 University Of Kentucky Research Foundation Use of lobeline compounds in the treatment of central nervous system diseases and pathologies
FR2794742B1 (fr) * 1999-06-11 2005-06-03 Sanofi Synthelabo Nouveaux derives du benzene, un procede pour leur preparation et les compositions pharmaceutiques les contenant
US6632666B2 (en) * 2000-01-14 2003-10-14 Biolife Solutions, Inc. Normothermic, hypothermic and cryopreservation maintenance and storage of cells, tissues and organs in gel-based media
CA2398446A1 (en) * 2000-04-18 2001-10-25 Agouron Pharmaceuticals, Inc. Pyrazoles for inhibiting protein kinases
CA2529746C (en) * 2003-06-16 2010-08-03 Andrx Pharmaceuticals, Llc Oral extended-release composition
GB2410947B (en) * 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds
WO2006053067A2 (en) * 2004-11-09 2006-05-18 Prestwick Pharmaceuticals, Inc. Combination of amantadine and a tetrabenazine compound for treating hyperkinetic disorders
KR100682506B1 (ko) * 2005-01-18 2007-02-15 (주)젠크로스 프라지콴텔, 또는 이의 염을 포함하는 약학 조성물
GB0516168D0 (en) * 2005-08-05 2005-09-14 Cambridge Lab Ireland Ltd Pharmaceutical compounds
GB2462611A (en) * 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
US20110053866A1 (en) * 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
GB2463283A (en) * 2008-09-08 2010-03-10 Cambridge Lab 3,11b-cis-dihydrotetrabenazine for use in treating asthma
GB2463451A (en) * 2008-09-08 2010-03-17 Cambridge Lab 3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia
GB2463452A (en) * 2008-09-08 2010-03-17 Cambridge Lab Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof

Also Published As

Publication number Publication date
ZA200800905B (en) 2010-04-28
CY1108653T1 (el) 2014-04-09
ATE522215T1 (de) 2011-09-15
EP2027861A1 (en) 2009-02-25
AU2006268098A1 (en) 2007-01-18
DE602006002982D1 (de) 2008-11-13
CN101282726A (zh) 2008-10-08
WO2007007105A1 (en) 2007-01-18
PL1885363T3 (pl) 2009-05-29
CA2615077A1 (en) 2007-01-18
JP2009501202A (ja) 2009-01-15
ME01629B (me) 2010-06-30
HK1111085A1 (en) 2008-08-01
EP1885363B1 (en) 2008-10-01
SI1885363T1 (sl) 2009-02-28
ES2314931T3 (es) 2009-03-16
US20080319000A1 (en) 2008-12-25
ATE409481T1 (de) 2008-10-15
RS50626B (sr) 2010-06-30
HRP20080677T3 (hr) 2009-02-28
DK1885363T3 (da) 2008-12-08
EP1885363A1 (en) 2008-02-13
KR20080030666A (ko) 2008-04-04
PT1885363E (pt) 2009-01-08
RU2409365C2 (ru) 2011-01-20
AU2006268098B2 (en) 2011-02-17
RU2008105590A (ru) 2009-08-20
EP2027861B1 (en) 2011-08-31
NZ565522A (en) 2010-04-30

Similar Documents

Publication Publication Date Title
GB0514501D0 (en) Pharmaceutical compounds
ZA200703110B (en) Compounds, compositions and methods of inhibiting α-synuclein toxicity
IL189500A (en) 4, 2-Diaminopyrimidines are preserved in position 5, containing pharmaceutical preparations and using them to prepare a drug for the treatment of 3x2p receptor mediated diseases and 2/3 x2p
WO2006091693A3 (en) Extending time to disease progression or survival in cancer patients using a her dimerization inhibitor
ZA200802897B (en) New pyrimidine derivatives and their use in therapy as well as the use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of Alzheimer's Disease
SG10201912182UA (en) Improved modalities for the treatment of degenerative diseases of the retina
WO2006122186A3 (en) 1,4-diphenyl-3-hydroxyalkyl-2-azetidinone derivatives for treating hypercholestrolemia
ES2414872T8 (es) Terapia combinada para la prevención o tratamiento de la enfermedad de Alzheimer y kit correspondiente
ATE534391T1 (de) 3,11b-cis-dihydrotetrabenazin zur behandlung von psychosen
EA200601837A1 (ru) Бензоксазины для лечения заболеваний дыхательных путей
IL189104A (en) Pharmaceutical preparation containing lasalazide or sodium balasalazide for use in the treatment of gastrointestinal disorders.
EP1940373B8 (en) 1-fluoro-1-deoxy-scyllo-inositol for the treatment of alzheimer's disease
ZA200604114B (en) Use of substituted 2-aminotetralines for the preventative treatment of parkinson's disease
WO2006108582A3 (en) Human marker genes and agents for diagnosis, treatment and prophylaxis of cardiovascular disorders and artherosclerosis
BRPI0508051A (pt) derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes
GB0410398D0 (en) The treatment of respiratory disease
WO2008016640A3 (en) Use of poloxamer for the prevention and/or treatment of heart failure
GB0516168D0 (en) Pharmaceutical compounds
IL184849A0 (en) Organic compounds useful for the treatment of alzheimer's disease, their use and method of preparation
PT2366393E (pt) Roflumilaste para o tratamento da hipertensão pulmonar
EP1896074A4 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF CORONARY ARTERY DISEASE
DK1732648T3 (da) Sygdomsbehandling
WO2006059121A3 (en) Modulators of spindle checkpoint kinases and a taxol
RU2002103738A (ru) Компонент, обеспечивающий поверхностно-активные свойства композиций-аналогов препаратов для заместительной сурфактантной терапии легочных заболеваний
WO2007054566A3 (en) Use of fenofibrate or a derivative thereof for preventing diabetic retinopathy

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)